Skip to main content
OpenTrials
Completed

NCT Number: NCT04405414

EffectS of CAnnabidiol in Patients: Evaluation

Since its recent marketizing in France, the cannabidiol (CBD), a major component of cannabis, is used in many over-the-counter products in France. Some painful patients or patients suffering from addiction seem to use the CBD in search of therapeutic effects. Yet, there are no data available for patients in algology and addictology, particularly with regard to the prevalence of the use of CBD, the effects sought and felt. Faced with the emergence of the use of a substance with a therapeutic purpose but outside a medical framework and without monitoring of adverse effects, it becomes essential to characterize the use of CBD. The main objective of the study is therefore to assess the prevalence of CBD users in algology and addictology departments. Secondary objectives are to characterize the use of CBD as well as the users of CBD, and to evaluate the impact of the use of CBD on other psychoactive substances use or current drug treatments and the drug liking of CBD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Substance-related Disorders Chemically-Induced Disorders Mental Disorders Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nantes University Hospital

Nantes, Loire-Atlantique, 44093, France

About this study

Physicians from algology and addictology departments will propose the study to all patients who meet the inclusion criteria during a medical consultation (in hospitalization or ambulatory care). If the patient agrees to participate, the non-opposition will be collected and the physician will complete a short form with sociodemographic data, medical history and contact details of the patient.

The form will be transmitted securely to the research staff that will perform a unique research evaluation face to face (when the patient is still hospitalized and available) or by phone (when the patient is not available during hospitalization or no longer hospitalized or in case of ambulatory care). The research evaluation includes data about the frequency and the duration of the use of all substances (CBD included) in the last 12 months and the frequency of current drug treatments. For patients with CBD use in the last 12 months, additional data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD.

A descriptive analysis will be carried out. The CBD user group and the CBD non-user group will be compared on all the variables collected. A multivariate analysis will be carried out in order to identify factors associated to CBD use in algology and addictology patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Minimum age of 18 years
  • Patients for whom hospital specialists in algology or addictology have been requested (for hospitalized or ambulatory cares) during the inclusion period.
  • Giving oral non opposition to participate.

Exclusion criteria

  • Adults under guardianship or curator
  • Patients unable to respond to the research evaluation (cerebral function disorder, difficulty to understand, read or write French language).

Treatment and study plan

Form

Other

Data regarding the use of CBD will be collected: the form, the route of administration, the effects sought and felt, the method of obtaining, the impact on other drugs and/or substances use and the drug liking of CBD

Primary outcomes

  1. Prevalence of CBD users

    Time frame: through study completion, an average of 2 year

    For all patients included in the study, the use of CBD during the last 12 months (yes or no) will be collected.

Secondary outcomes

  1. Characterization of the use of CBD

    Time frame: through study completion, an average of 2 year

    Prevalence of form, all effects sought and felt, method of obtaining and route of administration of CBD, frequency and duration of the use.

  2. Characterization of CBD users

    Time frame: through study completion, an average of 2 year

    Prevalence of CBD users (use of CBD in the last 12 months) according to patients' characteristics: age categories, sex, employment status, medical history, other psychoactive substances use, current drug treatments.

  3. Impact of the use of CBD

    Time frame: through study completion, an average of 2 year

    Proportion of CBD users who stopped, decreased, increased or initiated drug treatments in relation to the CBD use.

  4. CBD drug-liking

    Time frame: through study completion, an average of 2 year

    Mean on Visual Analog Scale (VAS) on drug liking for CBD and frequency of substances or drug treatments that would be taken as alternatives in the absence of CBD

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Observational Study of Cannabidiol Use in Patients Consulting in Addictology and/ or Algology Departments

Acronym: ESCAPE

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 28, 2020
Registry last updated
Sep 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.